When Cardiometabolic Disease Becomes the Default: A Conversation with Prof Naveed Sattar
Why cardiology can no longer treat diabetes, obesity, heart failure and kidney disease as separate problems
Episode 152 of Parallax brings Prof Naveed Sattar into conversation with Dr Ankur Kalra to reflect on a clinical reality that has become routine.
Diabetes, cardiovascular disease, heart failure, chronic kidney disease and obesity are no longer sequential diagnoses. They present together, evolve together and must increasingly be managed together.
As Professor Sattar puts it,
“What we are now seeing in clinics is not coincidence. These conditions are converging because the biology and the environment are pushing patients in the same direction.”
This episode is less about innovation and more about recognition. Recognition that cardiometabolic multimorbidity is no longer the exception. It is the dominant pattern of modern cardiovascular care.
Living longer with more disease
The clustering of cardiometabolic conditions reflects genuine progress. Patients survive myocardial infarction. They live long enough to develop heart failure. They live long enough for kidney disease to emerge.
But longevity tells only part of the story.
More people are living with obesity earlier in life and for longer periods. The downstream consequences type two diabetes, fatty liver disease, hypertension and accelerated vascular ageing are now embedded in everyday cardiology practice.
Professor Sattar captures this tension clearly,
“This is partly a success in keeping people alive longer, but it is also a societal failure.”
The result is a patient population carrying cumulative metabolic burden over decades rather than years.
Diabetes reconsidered through time
A recurring theme in EP 152 is the need to move away from simplistic labels. Diabetes has long been described as a coronary disease equivalent, yet duration and context matter more than diagnosis alone.
At the point of diagnosis, cardiovascular risk is elevated but not equivalent to established coronary artery disease. With longer duration, particularly beyond ten years and with insulin use, risk approaches equivalence.
This reframes diabetes as a time dependent amplifier of cardiovascular risk, shaped by adiposity, glycaemic exposure and accompanying comorbidity.
Why cardiologists can no longer outsource diabetes
For many years, cardiology remained unconvinced by glucose lowering therapies. HbA1c improved, but cardiovascular outcomes did not meaningfully change. That scepticism was understandable.
It is no longer defensible.
The emergence of SGLT2 inhibitors transformed the therapeutic landscape. Initially developed for diabetes, they are now foundational therapies for heart failure and chronic kidney disease, with benefits extending to patients without diabetes.
Professor Sattar is unambiguous,
“These are disease modifying drugs. They have changed how we treat heart failure and kidney disease, regardless of glucose.”
Their integration into guideline directed therapy represents a fundamental shift in cardiovascular medicine.
GLP one receptor agonists and atherosclerotic risk
The second inflection point discussed is the evolution of GLP one receptor agonists. What began as incretin based glucose management demonstrated unexpected cardiovascular benefit.
Across multiple trials, these agents reduced major adverse cardiovascular events, lowered stroke risk and delivered sustained, clinically meaningful weight loss.
Importantly, these effects extend beyond glycaemic control and complement the benefits of SGLT2 inhibitors. In patients with established cardiovascular disease and diabetes, the combination targets heart failure, atherosclerosis and metabolic dysfunction simultaneously.
As Professor Sattar notes,
“These drugs do something other therapies do not. They help patients lose weight and feel better, and that matters clinically.”
Weight loss as mechanism, not cosmetic outcome
A key reframing in EP 152 is how intentional weight loss is viewed. It is not cosmetic. It is not optional. It is mechanistic.
Sustained weight reduction improves blood pressure, insulin resistance, hepatic steatosis, sleep apnoea, joint disease and functional capacity. Unlike many cardiovascular therapies, it also improves lived experience.
This helps explain both clinical enthusiasm and public demand. Patients experience tangible benefit, not just improved biomarkers.
Cost remains the limiting factor
Despite compelling evidence, access remains constrained. In the United Kingdom, prescribing thresholds reflect population level cost considerations rather than individual benefit alone.
This tension is familiar. Statins followed a similar trajectory, initially restricted and later expanded as costs fell and evidence matured. Cardiometabolic therapies are likely to follow the same path.
Until then, clinicians must balance evidence, equity and feasibility within the systems they work in.
Obesity, environment and professional humility
One of the most important messages of EP 152 is the call for humility. Obesity is not primarily a failure of willpower. It is the predictable outcome of an increasingly obesogenic environment shaped by sleep disruption, screen exposure, food availability and portion size.
Professor Sattar is clear,
“If you have never lived with obesity, you cannot fully understand how hard it is to resist the environment.”
For professionals, this requires a shift from judgement to understanding and from moral framing to biological reality.
What this episode leaves behind
EP 152 does not conclude with an algorithm or a prescription checklist. It leaves a change in perspective.
Multimorbidity is no longer unusual. Cardiometabolic disease is no longer siloed. Collaboration across cardiology, endocrinology, nephrology and primary care is no longer optional.
This is an episode that sharpens awareness rather than offering certainty. It leaves you more attentive to how diseases accumulate, why they cluster, and what modern cardiovascular care now demands.
🎧 Parallax is produced by Radcliffe Cardiology in association with MakeADent.org.